The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
Open accessAbstract
Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway is activated under the interaction of a broad number of profibrotic/pro-inflammatory cytokines, such as IL-6, IL-11, and IL-13, among others, which are increased in different ILDs. Similarly, several growth factors over-expressed in ILDs, such as platelet-derived growth factor (PDGF), transforming growth factor β1 (TGF-β1), and fibroblast growth factor (FGF) activate JAK/STAT by canonical or non-canonical pathways, which indicates a predominant role of JAK/STAT in ILDs. Between the different JAK/STAT isoforms, it appears that JAK2/STAT3 are predominant, initiating cellular changes observed in ILDs. This review analyzes the expression and distribution of different JAK/STAT isoforms in ILDs lung tissue and different cell types related to ILDs, such as lung fibroblasts and alveolar epithelial type II cells and analyzes JAK/STAT activation. The effect of JAK/STAT phosphorylation on cellular fibrotic processes, such as proliferation, senescence, autophagy, endoplasmic reticulum stress, or epithelial/fibroblast to mesenchymal transition will be described. The small molecules directed to inhibit JAK/STAT activation were assayed in vitro and in in vivo models of pulmonary fibrosis, and different JAK inhibitors are currently approved for myeloproliferative disorders. Recent evidence indicates that JAK inhibitors or monoclonal antibodies directed to block IL-6 are used as compassionate use to attenuate the excessive inflammation and lung fibrosis related to SARS-CoV-2 virus. These altogether indicate that JAK/STAT pathway is an attractive target to be proven in future clinical trials of lung fibrotic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050 · cited 2×
“FGF is also increased in the lung of progressive fibrosing-ILD [53] and activated FGF-receptor phosphorylates STAT1, STAT3, and STAT5 [38,39,54].”
BackgroundBowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“In cancer, STAT3 activates genes of anti-autophagy proteins like BCL2, BCL2L1, and MCL1 [118], which disrupt the formation of the complex BECN1/PIK3C3, essential for autophagy [98].”
BackgroundMcGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Cellular senescence mediates fibrotic pulmonary disease
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613 · cited 1×
“Epithelial cells and fibroblasts from IPF lung tissue have increased senescence biomarkers p16 and p21, and senescence-associated β-galactosidase activity (SA-β-gal) [93], and show elevated senescence-associated secretory phenotype (SASP) components [94,95].”
BackgroundThe JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
Acute respiratory failure in COVID-19: is it “typical” ARDS?
Li, X., & Ma, X. (2020) · Critical Care · doi:10.1186/s13054-020-02911-9 · Cited by 673
Clark, J. D., Flanagan, M. E., & Telliez, J.-B. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401490p · Cited by 601
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0736-y · Cited by 590
Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
Milner, J. D., Vogel, T. P., Forbes, L., Ma, C. A., Stray-Pedersen, A., Niemela, J. E., Lyons, J. J., Engelhardt, K. R., Zhang, Y., Topcagic, N., et al. (2015) · Blood · doi:10.1182/blood-2014-09-602763 · Cited by 557
Kremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Hui, D. S. (2005) · Thorax · doi:10.1136/thx.2004.030205 · Cited by 531
Oxidative stress and pulmonary fibrosis
Cheresh, P., Kim, S.-J., Tulasiram, S., & Kamp, D. W. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.11.021 · Cited by 530
The role of STAT3 in autophagy
You, L., Wang, Z., Li, H., Shou, J., Jing, Z., Xie, J., Sui, X., Pan, H., & Han, W. (2015) · Autophagy · doi:10.1080/15548627.2015.1017192 · Cited by 515 · cited 1×
“Both nuclear and cytoplasmic STAT3s were found to contribute to the signaling of autophagy [119].”
BackgroundEpithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis
Korfei, M., Ruppert, C., Mahavadi, P., Henneke, I., Markart, P., Koch, M., Lang, G., Fink, L., Bohle, R.-M., Seeger, W., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200802-313oc · Cited by 514
Polak, S. B., Van Gool, I. C., Cohen, D., von der Thüsen, J. H., & van Paassen, J. (2020) · Modern Pathology · doi:10.1038/s41379-020-0603-3 · Cited by 481 · cited 1×
“As previously showed in Table 1, these characteristics are shared with those seen in ILDs [148].”
BackgroundCao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.019 · Cited by 456
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Cantini, F., Niccoli, L., Matarrese, D., Nicastri, E., Stobbione, P., & Goletti, D. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.017 · Cited by 436
Myall, K. J., Mukherjee, B., Castanheira, A. M., Lam, J. L., Benedetti, G., Mak, S. M., Preston, R., Thillai, M., Dewar, A., Molyneaux, P. L., et al. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202008-1002oc · Cited by 433
Lawson, W. E., Crossno, P. F., Polosukhin, V. V., Roldan, J., Cheng, D.-S., Lane, K. B., Blackwell, T. R., Xu, C., Markin, C., Ware, L. B., et al. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00382.2007 · Cited by 429
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Bousoik, E., & Montazeri Aliabadi, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 376
Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis
Parimon, T., Yao, C., Stripp, B. R., Noble, P. W., & Chen, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072269 · Cited by 375
Autophagy in Idiopathic Pulmonary Fibrosis
Patel, A. S., Lin, L., Geyer, A., Haspel, J. A., An, C. H., Cao, J., Rosas, I. O., & Morse, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041394 · Cited by 372
Follow-up chest radiographic findings in patients with MERS-CoV after recovery
Das, K. M., Lee, E. Y., Singh, R., Enani, M. A., Al Dossari, K., Van Gorkom, K., Larsson, S. G., & Langer, R. D. (2017) · Indian Journal of Radiology and Imaging · doi:10.4103/ijri.ijri_469_16 · Cited by 370 · cited 1×
“Some follow-up studies concluded that fibrosis appears as a common sequelae in severe SARS patients [153–155] and in a follow-up study of 36 patients surviving MERS, 33% had pulmonary fibrosis [156].”
BackgroundWu, X., Tao, P., Zhou, Q., Li, J., Yu, Z., Wang, X., Li, J., Li, C., Yan, M., Zhu, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15119 · Cited by 367
Evolving Concepts of Apoptosis in Idiopathic Pulmonary Fibrosis
Thannickal, V. J., & Horowitz, J. C. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-001tk · Cited by 364
Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs
Lawson, W. E., Cheng, D.-S., Degryse, A. L., Tanjore, H., Polosukhin, V. V., Xu, X. C., Newcomb, D. C., Jones, B. R., Roldan, J., Lane, K. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107559108 · Cited by 363
Chakraborty, D., Šumová, B., Mallano, T., Chen, C.-W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01236-6 · Cited by 356
Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies
Ojo, A. S., Balogun, S. A., Williams, O. T., & Ojo, O. S. (2020) · Pulmonary Medicine · doi:10.1155/2020/6175964 · Cited by 352
Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis
Phan, T. H. G., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Eid, A. H., Fois, A. G., Zinellu, A., Mangoni, A. A., & Pintus, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03693-7 · Cited by 351
IPF lung fibroblasts have a senescent phenotype
Álvarez, D., Cárdenes, N., Sellarés, J., Bueno, M., Corey, C., Hanumanthu, V. S., Peng, Y., D’Cunha, H., Sembrat, J., Nouraie, M., et al. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00220.2017 · Cited by 342
Insufficient autophagy in idiopathic pulmonary fibrosis
Araya, J., Kojima, J., Takasaka, N., Ito, S., Fujii, S., Hara, H., Yanagisawa, H., Kobayashi, K., Tsurushige, C., Kawaishi, M., et al. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00213.2012 · Cited by 325
Colomiere, M., Ward, A. C., Riley, C., Trenerry, M. K., Cameron-Smith, D., Findlay, J., Ackland, L., & Ahmed, N. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604794 · Cited by 320
Yan, Z., Gibson, S. A., Buckley, J. A., Qin, H., & Benveniste, E. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.014 · Cited by 318
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314 · cited 2×
“In cancer, STAT3 activates genes of anti-autophagy proteins like BCL2, BCL2L1, and MCL1 [118], which disrupt the formation of the complex BECN1/PIK3C3, essential for autophagy [98].”
BackgroundInterleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Ng, B., Dong, J., D’Agostino, G., Viswanathan, S., Widjaja, A. A., Lim, W.-W., Ko, N. S. J., Tan, J., Chothani, S. P., Huang, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1237 · Cited by 314
LIU, R.-Y., ZENG, Y., LEI, Z., WANG, L., YANG, H., LIU, Z., ZHAO, J., & ZHANG, H.-T. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2310 · Cited by 308
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Groner, B., & von Manstein, V. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.033 · Cited by 306
The role of the JAK/STAT signal pathway in rheumatoid arthritis
Malemud, C. J. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18776224 · Cited by 302
Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
Le, T.-T. T., Karmouty-Quintana, H., Melicoff, E., Le, T.-T. T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302470 · Cited by 299
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
Fragoulis, G. E., McInnes, I. B., & Siebert, S. (2019) · Rheumatology · doi:10.1093/rheumatology/key276 · Cited by 296
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.007 · Cited by 296
Antonio, G. E., Wong, K. T., Hui, D. S. C., Wu, A., Lee, N., Yuen, E. H. Y., Leung, C. B., Rainer, T. H., Cameron, P., Chung, S. S. C., et al. (2003) · Radiology · doi:10.1148/radiol.2283030726 · Cited by 290
Baricitinib restrains the immune dysregulation in patients with severe COVID-19
Bronte, V., Ugel, S., Tinazzi, E., Vella, A., De Sanctis, F., Canè, S., Batani, V., Trovato, R., Fiore, A., Petrova, V., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci141772 · Cited by 281
Antoniou, K. M., Margaritopoulos, G. A., Tomassetti, S., Bonella, F., Costabel, U., & Poletti, V. (2014) · European Respiratory Review · doi:10.1183/09059180.00009113 · Cited by 274
Forbes, L. R., Vogel, T. P., Cooper, M. A., Castro-Wagner, J., Schussler, E., Weinacht, K. G., Plant, A. S., Su, H. C., Allenspach, E. J., Slatter, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.020 · Cited by 268
Shen, Y., Devgan, G., Darnell, J. E., & Bromberg, J. F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1543 · Cited by 249
Meares, G. P., Liu, Y., Rajbhandari, R., Qin, H., Nozell, S. E., Mobley, J. A., Corbett, J. A., & Benveniste, E. N. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00980-14 · Cited by 231
Barbas-Filho, J. V., Ferreira, M. A., Sesso, A., Kairalla, R. A., Carvalho, C. R. R., & Capelozzi, V. L. (2001) · Journal of Clinical Pathology · doi:10.1136/jcp.54.2.132 · Cited by 229
Tocilizumab: The first interleukin-6-receptor inhibitor
Sebba, A. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070449 · Cited by 214
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
Elli, E. M., Baratè, C., Mendicino, F., Palandri, F., & Palumbo, G. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01186 · Cited by 207
What Every Radiologist Should Know about Idiopathic Interstitial Pneumonias
Mueller-Mang, C., Grosse, C., Schmid, K., Stiebellehner, L., & Bankier, A. A. (2007) · RadioGraphics · doi:10.1148/rg.273065130 · Cited by 202
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
Seif, F., Aazami, H., Khoshmirsafa, M., Kamali, M., Mohsenzadegan, M., Pornour, M., & Mansouri, D. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000508247 · Cited by 197
Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review
Fabre, A., Marchal, S., Barlogis, V., Mari, B., Barbry, P., Rohrlich, P.-S., Forbes, L. R., Vogel, T. P., & Giovannini-Chami, L. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.018 · Cited by 194
Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., & Agarwal, S. K. (2016) · The FASEB Journal · doi:10.1096/fj.15-273953 · Cited by 193 · cited 7×
“Further, STAT3 regulates IL-6–mediated and TGF-β1–mediated myofibroblast differentiation in murine lung fibroblasts [30], and inhibition of STAT3 was found to reduce TGFβ1-induced FMT in fibroblasts, and ameliorate skin fibrosis in two mouse models of systemic sclerosis [82].”
BackgroundInfluentialThe JAK2 pathway is activated in idiopathic pulmonary fibrosis
Milara, J., Hernandez, G., Ballester, B., Morell, A., Roger, I., Montero, P., Escrivá, J., Lloris, J. M., Molina-Molina, M., Morcillo, E., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0728-9 · Cited by 188
Self-citationBaricitinib: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0723-3 · Cited by 186
Progression of fibrosing interstitial lung disease
Wong, A. W., Ryerson, C. J., & Guler, S. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-1296-3 · Cited by 185
COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection
Lechowicz, K., Drożdżal, S., Machaj, F., Rosik, J., Szostak, B., Zegan-Barańska, M., Biernawska, J., Dabrowski, W., Rotter, I., & Kotfis, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061917 · Cited by 184
Zhang, X., Zhang, Y., Qiao, W., Zhang, J., & Qi, Z. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106749 · Cited by 182
Walford, H. H., & Doherty, T. A. (2013) · JAK-STAT · doi:10.4161/jkst.25301 · Cited by 177
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
Li, P., Huang, T., Zou, Q., Liu, D., Wang, Y., Tan, X., Wei, Y., & Qiu, H. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801199 · Cited by 174
Moodley, Y. P., Misso, N. L. A., Scaffidi, A. K., Fogel-Petrovic, M., McAnulty, R. J., Laurent, G. J., Thompson, P. J., & Knight, D. A. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2002-0262oc · Cited by 173
Lescoat, A., Lelong, M., Jeljeli, M., Piquet-Pellorce, C., Morzadec, C., Ballerie, A., Jouneau, S., Jego, P., Vernhet, L., Batteux, F., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114103 · Cited by 173
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Satarker, S., Tom, A. A., Shaji, R. A., Alosious, A., Luvis, M., & Nampoothiri, M. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2020.1855921 · Cited by 171
Liu, T., Jin, H., Ullenbruch, M., Hu, B., Hashimoto, N., Moore, B., McKenzie, A., Lukacs, N. W., & Phan, S. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3425 · Cited by 167
Moodley, Y. P., Scaffidi, A. K., Misso, N. L., Keerthisingam, C., McAnulty, R. J., Laurent, G. J., Mutsaers, S. E., Thompson, P. J., & Knight, D. A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63658-9 · Cited by 165 · cited 1×
“In lung fibroblasts derived from IPF patients, stimulation with IL-6 induced proliferation, and a transient STAT3 activation, while in normal fibroblasts, IL-6 stimulation reduced proliferation through STAT3 signaling [24].”
BackgroundFibroblast senescence in the pathology of idiopathic pulmonary fibrosis
Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Burgess, J. K., Mutsaers, S. E., Prele, C. M., Schuliga, M., Grainge, C. L., & Knight, D. A. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00037.2018 · Cited by 163
Epithelial-mesenchymal transition: An emerging target in tissue fibrosis
Li, M., Luan, F., Zhao, Y., Hao, H., Zhou, Y., Han, W., & Fu, X. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215597194 · Cited by 161
STAT3 and its targeting inhibitors in osteosarcoma
Liu, Y., Liao, S., Bennett, S., Tang, H., Song, D., Wood, D., Zhan, X., & Xu, J. (2021) · Cell Proliferation · doi:10.1111/cpr.12974 · Cited by 158
Mechanisms of Oncostatin M-Induced Pulmonary Inflammation and Fibrosis
Mozaffarian, A., Brewer, A. W., Trueblood, E. S., Luzina, I. G., Todd, N. W., Atamas, S. P., & Arnett, H. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7243 · Cited by 153
O'Donoghue, R. J. J., Knight, D. A., Richards, C. D., Prêle, C. M., Lau, H. L., Jarnicki, A. G., Jones, J., Bozinovski, S., Vlahos, R., Thiem, S., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100604 · Cited by 152 · cited 2×
“Its active form was detected in areas of dense fibrosis in IPF patients, more accurately in the nucleus of pulmonary artery cells, in myofibroblasts, and the nuclei of alveolar epithelial cells (AECs) [23,31,49,59,61].”
BackgroundAngiogenic cytokines in patients with idiopathic interstitial pneumonia
Simler, N., Brenchley, P. E., Horrocks, A. W., Greaves, S. M., Hasleton, P. S., & Egan, J. J. (2004) · Thorax · doi:10.1136/thx.2003.009860 · Cited by 148
Hill, C. N., Jones, M. G., Davies, D. E., & Wang, Y. (2019) · Journal of Lung Health and Diseases · doi:10.29245/2689-999x/2019/2.1149 · Cited by 147
Dynamics and non-canonical aspects of JAK/STAT signalling
Mohr, A., Chatain, N., Domoszlai, T., Rinis, N., Sommerauer, M., Vogt, M., & Müller‐Newen, G. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.09.005 · Cited by 132
Nadeau, K. C., Hwa, V., & Rosenfeld, R. G. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.12.042 · Cited by 129
Zhang, C., Wu, Z., Li, J., Tan, K., Yang, W., Zhao, H., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26634 · Cited by 129
Waris, G., Tardif, K. D., & Siddiqui, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01300-x · Cited by 128
Tyrosine kinase signaling in fibrotic disorders
Beyer, C., & Distler, J. H. W. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.06.008 · Cited by 127
Pechkovsky, D. V., Prêle, C. M., Wong, J., Hogaboam, C. M., McAnulty, R. J., Laurent, G. J., Zhang, S. S.-M., Selman, M., Mutsaers, S. E., & Knight, D. A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.12.022 · Cited by 127
JAK Inhibitors: Prospects in Connective Tissue Diseases
You, H., Xu, D., Zhao, J., Li, J., Wang, Q., Tian, X., Li, M., & Zeng, X. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08786-6 · Cited by 126
Localization of Platelet-Derived Growth Factor and Insulin-Like Growth Factor I in the Fibrotic Lung
Homma, S. A., Nagaoka, I., Abe, H., Takahashi, K., Seyama, K., Nukiwa, T., & Kira, S. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.6.8520779 · Cited by 124
1-Year Pulmonary Function and Health Status in Survivors of Severe Acute Respiratory Syndrome
Ong, K.-C., Ng, A. W., Lee, L., Kaw, G. J. L., Kwek, S. K., Leow, M. K., & Earnest, A. (2005) · CHEST Journal · doi:10.1378/chest.128.3.1393 · Cited by 121
Therapeutic Targeting of IL-4- and IL-13-Responsive Cells in Pulmonary Fibrosis
Jakubzick, C., Kunkel, S. L., Puri, R. K., & Hogaboam, C. M. (2004) · Immunologic Research · doi:10.1385/ir:30:3:339 · Cited by 118
Lindahl, G. E., Stock, C. J. W., Shiwen, X., Leoni, P., Sestini, P., Howat, S., Bou–Gharios, G., Nicholson, A. G., Denton, C. P., Grutters, J. C., et al. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-80 · Cited by 107
The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib
Wang, W., Bhattacharyya, S., Marangoni, R. G., Carns, M. A., Dennis‐Aren, K., Yeldandi, A. V., Wei, J., & Varga, J. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319865367 · Cited by 107
Ng, B., Cook, S. A., & Schäfer, S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00531-5 · Cited by 107
Update in diagnosis and management of interstitial lung disease
Mikolasch, T., Garthwaite, H. S., & Porter, J. C. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-2-146 · Cited by 106
Kagan, P., Sultan, M., Tachlytski, I., Safran, M., & Ben‐Ari, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176173 · Cited by 103
Gagiannis, D., Steinestel, J., Hackenbroch, C., Schreiner, B., Hannemann, M., Bloch, W., Umathum, V. G., Gebauer, N., Rother, C., Stahl, M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587517 · Cited by 103
O’Dwyer, D. N., Ashley, S. L., & Moore, B. B. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00221.2016 · Cited by 99
The cytokine storm of COVID-19: a spotlight on prevention and protection
Pearce, L., Davidson, S. M., & Yellon, D. M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1783243 · Cited by 99
Furini, F., Carnevale, A., Casoni, G. L., Guerrini, G., Cavagna, L., Govoni, M., & Scirè, C. A. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00246 · Cited by 97
STAT5B deficiency: Impacts on human growth and immunity
Hwa, V. (2015) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2015.12.006 · Cited by 96
Cryptogenic organizing pneumonia
Cordier, J.-F. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.06.003 · Cited by 94
Nho, R. S., & Hergert, P. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094616 · Cited by 93
JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate
Chen, Y., Surinkaew, S., Naud, P., Qi, X., Gillis, M., Shi, Y., Tardif, J., Dobrev, D., & Nattel, S. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx004 · Cited by 93
Aydemir, M. N., Aydemir, H. B., Korkmaz, E. M., Budak, M., Çekin, N., & Pınarbaşı, E. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.101012 · Cited by 93
Xiao, J., Gong, Y., Chen, Y., Yu, D., Wang, X., Zhang, X., Dou, Y., Liu, D., Cheng, G., Lu, S., et al. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00428.2016 · Cited by 91
Shaw, R. J., Benedict, S. H., Clark, R. A. F., & King, T. E. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/143.1.167 · Cited by 90
Chen, Y.-L., Zhang, X., Bai, J., Gai, L., Xl, Y., Zhang, L., Xu, Q., Yx, Z., Xu, L., Li, H., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.154 · Cited by 88
Update in diagnosis and management of interstitial lung disease
Mikolasch, T., Garthwaite, H. S., & Porter, J. C. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s71 · Cited by 88
Wu, C., Zheng, S., Chen, Y., & Zheng, M. (2020) · medRxiv · doi:10.1101/2020.02.11.20022228 · Cited by 85
Milara, J., Ballester, B., Morell, A., Ortiz, J. L., Escrivá, J., Fernández, E., Pérez‐Vizcaíno, F., Cogolludo, A. L., Pastor, E., Artigues, E., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210728 · Cited by 84
Self-citationZhou, T., Casanova, N. G., Pouladi, N., Wang, T., Lussier, Y. A., Knox, K. S., & Garcia, J. G. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-04109-6 · Cited by 82
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies
Passalacqua, G., Mincarini, M., Colombo, D., Troisi, G., Ferrari, M., Bagnasco, D., Balbi, F., Riccio, A., & Canonica, G. W. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.05.007 · Cited by 80
Park, C., Chung, S. W., Ki, S. Y., Lim, G.-I., Uh, S., Kim, Y. H., Choi, D. L., Park, J. S., Lee, D. W., & Kitaichi, M. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9906007 · Cited by 78
STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases
Lorenzini, T., Dotta, L., Giacomelli, M., Vairo, D., & Badolato, R. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0516-237rr · Cited by 78
STAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts
Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Wei, L., Schuliga, M. J., Jaffar, J., Westall, G. P., Hansbro, P. M., Prêle, C. M., Mutsaers, S. E., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0328oc · Cited by 77
Jakubzick, C., Choi, E. S., Carpenter, K. J., Kunkel, S. L., Evanoff, H. L., Martínez, F. J., Flaherty, K. R., Toews, G. B., Colby, T. V., Travis, W. D., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63759-5 · Cited by 76
Strand, V., van Vollenhoven, R., Lee, E. B., Fleischmann, R., Zwillich, S. H., Gruben, D. C., Koncz, T., Wilkinson, B. E., & Wallenstein, G. V. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kev442 · Cited by 76
Wang, J., Wang, B. J., Yang, J., Wang, M., Chen, C., Luo, G., & He, W. (2020) · PubMed · doi:10.3760/cma.j.cn501120-20200307-00132 · Cited by 76
Shieh, J., Tseng, H., Jung, F., Yang, S., & Lin, J. (2019) · Mediators of Inflammation · doi:10.1155/2019/7947596 · Cited by 74
Fibroblast‐specific IL11 signaling drives chronic inflammation in murine fibrotic lung disease
Ng, B., Dong, J., Viswanathan, S., Widjaja, A. A., Paleja, B. S., Adami, E., Ko, N. S. J., Wang, M., Lim, S., Tan, J., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001045rr · Cited by 74
Sendo, S., Saegusa, J., Yamada, H., Nishimura, K., & Morinobu, A. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1963-2 · Cited by 68
Jägle, S., Heeg, M., Grün, S., Rensing‐Ehl, A., Maccari, M. E., Klemann, C., Jones, N., Lehmberg, K., Bettoni, C., Warnatz, K., et al. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.108316 · Cited by 65
Paukku, K., Valgeirsdóttir, S., Saharinen, P., Bergman, M., Heldin, C., & Silvennoinen, O. (2000) · Biochemical Journal · doi:10.1042/bj3450759 · Cited by 65
Zhang, Y., Dees, C., Beyer, C., Lin, N.-Y., Distler, A., Zerr, P., Palumbo, K., Susok, L., Kreuter, A., Distler, O., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204256 · Cited by 64
Sun, Q., Liu, L., Mandal, J., Molino, A., Stolz, D., Tamm, M., Lu, S., & Roth, M. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.01.004 · Cited by 63
Zhang, Y., Liang, R., Chen, C.-W., Mallano, T., Dees, C., Distler, A., Reich, A., Bergmann, C., Ramming, A., Gelse, K., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210911 · Cited by 61
Ma, X., Chen, R., Liu, X., Xie, J., Si, K., & Duan, L. (2013) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.4314/ajtcam.v10i3.10 · Cited by 60
Singer, J. W., Al‐Fayoumi, S., Taylor, J. A., Velichko, S., & O’Mahony, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222944 · Cited by 60
Lung alveolar epithelium and interstitial lung disease
Corvol, H., Flamein, F., Epaud, R., Clément, A., & Guillot, L. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.02.009 · Cited by 59
The role of apoptosis in pulmonary fibrosis
Uhal, B. D. (2008) · European Respiratory Review · doi:10.1183/09059180.00010906 · Cited by 59
Bader‐Meunier, B., Hadchouel, A., Berteloot, L., Polivka, L., Béziat, V., Casanova, J., & Lévy, R. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216983 · Cited by 59
d’Alessandro, M., Perillo, F., Refini, R. M., Bergantini, L., Bellisai, F., Selvi, E., Cameli, P., Manganelli, S., Conticini, E., Cantarini, L., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106748 · Cited by 59
Hoffmann‐Vold, A., Weigt, S. S., Saggar, R., Palchevskiy, V., Volkmann, E. R., Liang, L. L., Ross, D. J., Ardehali, A. A., Lynch, J. P., & Belperio, J. A. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.050 · Cited by 58
STAT3: A Central Mediator of Pulmonary Fibrosis?
Prêle, C. M., Yao, E., O’Donoghue, R. J. J., Mutsaers, S. E., & Knight, D. A. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-007aw · Cited by 55
Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
Fintha, A., Gasparics, Á., Rosivall, L., & Sebe, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00388 · Cited by 54
Paukku, K., Valgeirsdóttir, S., Saharinen, P., Bergman, M., Heldin, C., & Silvennoinen, O. (2000) · PubMed Central · Cited by 53
Li, H., Zhao, X., Wang, J., Zong, M., & Yang, H. (2016) · Gene · doi:10.1016/j.gene.2016.09.037 · Cited by 53
Gutiérrez, M., Scaglia, P. A., Keselman, A. C., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.01.016 · Cited by 52
Balcı, S., Ekinci, R. M. K., de Jesus, A. A., Goldbach‐Mansky, R. T., & Yilmaz, M. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.108273 · Cited by 48
Successful Treatment of Interstitial Lung Disease in STAT3 Gain-of-Function Using JAK Inhibitors
Silva‐Carmona, M., Vogel, T. P., Marchal, S., Guesmi, M., Dubus, J. ‐., Leroy, S., Fabre, A., Barlogis, V., Forbes, L. R., & Giovannini‐Chami, L. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1204le · Cited by 48
Shi, K., Jiang, J., Ma, T., et al. (2014) · PubMed · Cited by 42
The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2
Luo, J., Lu, S., Yu, M., Zhu, L., Zhu, C., Li, C., Fang, J., Zhu, X., & Wang, X. (2020) · Gene · doi:10.1016/j.gene.2020.145325 · Cited by 37
Suzuki, T., McCarthy, C., Carey, B. C., Borchers, M. T., Beck, D. C., Wikenheiser‐Brokamp, K. A., Black, D., Chalk, C., & Trapnell, B. C. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0294oc · Cited by 34
Atabati, E., Dehghani-Samani, A., & Moghaddam, S. G. M. (2020) · Canadian Journal of Respiratory Therapy · doi:10.29390/cjrt-2020-021 · Cited by 33
Roles of STAT3 in Protein Secretion Pathways during the Acute-Phase Response
Ahyi, A.-N. N., Quinton, L. J., Jones, M. R., Ferrari, J. D., Pepper-Cunningham, Z. A., Mella, J. R., Remick, D. G., & Mizgerd, J. P. (2013) · Infection and Immunity · doi:10.1128/iai.01332-12 · Cited by 32
Meletiadis, J., Tsiodras, S., & Tsirigotis, P. D. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00326-1 · Cited by 29
Lin, X., Liu, M., Liu, Y., Hu, H., Pan, Y. ⁄., Zou, W.-W., Fan, X., & Hu, X. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3228 · Cited by 28
Defining genetic risk factors for scleroderma-associated interstitial lung disease
Stock, C. J. W., Lauretis, A. D., Visca, D., Daccord, C., Kokosi, M. A., Kouranos, V., Margaritopoulos, G. A., George, P. M., Molyneaux, P. L., Nihtyanova, S. I., et al. (2020) · Clinical Rheumatology · doi:10.1007/s10067-019-04922-6 · Cited by 25
Zhou, G., Xu, Y., He, B., Ma, R., Wang, Y., Chang, Y., Xie, Y., Wu, L., Huang, J., & Xiao, Z. (2020) · Brain and Behavior · doi:10.1002/brb3.1529 · Cited by 22
Vasarmidi, E., Sarantoulaki, S., Trachalaki, A., Margaritopoulos, G. A., Bibaki, E., Spandidos, D. A., Tzanakis, Ν., & Antoniou, K. M. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9356 · Cited by 17
Conca, W., Weheba, I., Abouzied, M., Abdelsayed, A., Aleyouni, Y., Mutairy, E. A., Bakshi, N., & Khalid, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585761 · Cited by 16
Wang, Y., Li, Y., Wang, X., Li, X.-Z., Chen, Y., Yang, L., & Ming, H. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2407239 · Cited by 12
Jaśkiewicz, K., Mycroft, K., Maskey‐Warzęchowska, M., Paralusz-Stec, K., Siemiez, N., Nejman‐Gryz, P., Barnaś, M., Krenke, R., & Górska, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082523 · Cited by 7
Cited by
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Macrophage STING signaling promotes fibrosis in benign airway stenosis via an IL6-STAT3 pathway
Chen, Y., Yang, C., Miao, Y., Shi, D., Li, X., Tian, S., Zhang, Y., Xu, C., Dong, Y., Han, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55170-5 · Cited by 51
Metadata
- Authors
- Montero, P., Milara, J., Roger, I., & Cortijo, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-09
- Volume
- 22
- Issue
- 12
- Pages
- 6211
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3170001459
- Cited by
- 254
- References
- 156
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.